BR112022026080A2 - Composto, composições farmacêuticas, compostos de fórmula i ou ii, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção - Google Patents
Composto, composições farmacêuticas, compostos de fórmula i ou ii, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invençãoInfo
- Publication number
- BR112022026080A2 BR112022026080A2 BR112022026080A BR112022026080A BR112022026080A2 BR 112022026080 A2 BR112022026080 A2 BR 112022026080A2 BR 112022026080 A BR112022026080 A BR 112022026080A BR 112022026080 A BR112022026080 A BR 112022026080A BR 112022026080 A2 BR112022026080 A2 BR 112022026080A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- formula
- pharmaceutical compositions
- prevention
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPOSTO, COMPOSIÇÕES FARMACÊUTICAS, COMPOSTOS DE FÓRMULA I OU II, MÉTODO PARA O TRATAMENTO OU PREVENÇÃO DE ADENOCARCINOMA PULMONAR, USO DE COMPOSTOS E INVENÇÃO. A presente invenção fornece composto de fórmula I ou II: em que X1, X3, R1, R2, R3, R4 e R5 são conforme descritos neste documento, bem como os sais farmaceuticamente aceitáveis dos mesmos. Além disso, a presente invenção refere-se à fabricação dos compostos de fórmula I, composições farmacêuticas que os compreendem e seu uso como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20181341 | 2020-06-22 | ||
PCT/EP2021/066725 WO2021259815A1 (en) | 2020-06-22 | 2021-06-21 | Amidopyrimidone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022026080A2 true BR112022026080A2 (pt) | 2023-01-17 |
Family
ID=71120055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022026080A BR112022026080A2 (pt) | 2020-06-22 | 2021-06-21 | Composto, composições farmacêuticas, compostos de fórmula i ou ii, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230227449A1 (pt) |
EP (1) | EP4168394A1 (pt) |
JP (1) | JP2023531021A (pt) |
KR (1) | KR20230027042A (pt) |
CN (1) | CN115867541A (pt) |
AR (1) | AR122704A1 (pt) |
AU (1) | AU2021295413A1 (pt) |
BR (1) | BR112022026080A2 (pt) |
CA (1) | CA3181790A1 (pt) |
CL (1) | CL2022003646A1 (pt) |
CO (1) | CO2023000056A2 (pt) |
CR (1) | CR20220638A (pt) |
IL (1) | IL297879A (pt) |
MX (1) | MX2022015886A (pt) |
PE (1) | PE20230685A1 (pt) |
TW (1) | TW202216707A (pt) |
WO (1) | WO2021259815A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115215862A (zh) * | 2021-04-19 | 2022-10-21 | 武汉人福创新药物研发中心有限公司 | 嘧啶酮化合物及其用途 |
CN114751856A (zh) * | 2022-03-27 | 2022-07-15 | 江苏壹药新材料有限公司 | 一种5-碘-6-甲基烟腈的合成方法 |
WO2024002024A1 (zh) * | 2022-06-27 | 2024-01-04 | 石药集团中奇制药技术(石家庄)有限公司 | 三环类化合物及其用途 |
CN116283800B (zh) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | 氧代喹唑啉类化合物及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1958666A1 (en) | 2007-02-13 | 2008-08-20 | Speedel Experimenta AG | Heterocyclic-substituted alkanamides as therapeutic compounds |
WO2009111547A1 (en) | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
US20100036123A1 (en) | 2008-08-07 | 2010-02-11 | Wyeth | Process for the preparation of 2,4-dichloro-7h-pyrrolo[2,3h]quinazoline |
CA2750708A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators |
US11452717B2 (en) | 2017-01-10 | 2022-09-27 | Sanford Burnham Prebys Medical Discovery Institute | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof |
AU2019395338A1 (en) * | 2018-12-10 | 2021-07-29 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
-
2021
- 2021-06-21 EP EP21735633.6A patent/EP4168394A1/en active Pending
- 2021-06-21 AU AU2021295413A patent/AU2021295413A1/en active Pending
- 2021-06-21 TW TW110122553A patent/TW202216707A/zh unknown
- 2021-06-21 CR CR20220638A patent/CR20220638A/es unknown
- 2021-06-21 CN CN202180044144.5A patent/CN115867541A/zh active Pending
- 2021-06-21 PE PE2022002951A patent/PE20230685A1/es unknown
- 2021-06-21 WO PCT/EP2021/066725 patent/WO2021259815A1/en active Application Filing
- 2021-06-21 KR KR1020227044191A patent/KR20230027042A/ko unknown
- 2021-06-21 IL IL297879A patent/IL297879A/en unknown
- 2021-06-21 BR BR112022026080A patent/BR112022026080A2/pt unknown
- 2021-06-21 MX MX2022015886A patent/MX2022015886A/es unknown
- 2021-06-21 CA CA3181790A patent/CA3181790A1/en active Pending
- 2021-06-21 JP JP2022578796A patent/JP2023531021A/ja active Pending
- 2021-06-22 AR ARP210101713A patent/AR122704A1/es unknown
-
2022
- 2022-12-19 US US18/068,407 patent/US20230227449A1/en active Pending
- 2022-12-19 CL CL2022003646A patent/CL2022003646A1/es unknown
-
2023
- 2023-01-04 CO CONC2023/0000056A patent/CO2023000056A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021259815A1 (en) | 2021-12-30 |
CL2022003646A1 (es) | 2023-08-04 |
MX2022015886A (es) | 2023-01-24 |
CO2023000056A2 (es) | 2023-03-27 |
US20230227449A1 (en) | 2023-07-20 |
TW202216707A (zh) | 2022-05-01 |
EP4168394A1 (en) | 2023-04-26 |
CN115867541A (zh) | 2023-03-28 |
AR122704A1 (es) | 2022-09-28 |
IL297879A (en) | 2023-01-01 |
JP2023531021A (ja) | 2023-07-20 |
CA3181790A1 (en) | 2021-12-30 |
PE20230685A1 (es) | 2023-04-21 |
CR20220638A (es) | 2023-01-31 |
AU2021295413A1 (en) | 2022-12-01 |
KR20230027042A (ko) | 2023-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022026080A2 (pt) | Composto, composições farmacêuticas, compostos de fórmula i ou ii, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção | |
BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
BR112018009281A8 (pt) | composições para tratar atrofia muscular espinhal | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
BR112018001720A2 (pt) | compostos de derivado de 1,3,4-oxadiazol sulfonamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
BR112016023679A2 (pt) | derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos | |
BR112016016844A2 (pt) | Compostos heterocíclicos | |
BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
BR112018068532A2 (pt) | combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
BR112021017604A2 (pt) | Compostos úteis na terapia para hiv | |
BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
BR112022006279A2 (pt) | Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 | |
BR112019004254A2 (pt) | inibidores da dopamina-b-hidroxilase penetrantes da barreira hematoencefálica | |
BR112022006018A2 (pt) | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 | |
BR112021023770A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
BR112021021284A2 (pt) | Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra | |
BR112023024551A2 (pt) | Análogos de triazolo-pirimidina para tratamento de doenças relacionadas à inibição de recq helicase de síndrome de werner (wrn) | |
BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
BR112023025318A2 (pt) | Derivados de triazina e seu uso no tratamento do câncer | |
BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso |